### SESSION #1  INSULIN RESISTANCE, OBESITY AND CO-MORBIDITIES
**Chairs:** Ronald M. Krauss, MD  •  Paul Zimmet, AO, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:10 pm</td>
<td>Insulin Resistance: All You Wanted to Know - Finally Get the Right Answer</td>
<td>Ralph A. DeFronzo, MD</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>Effect of Very Low Carb vs Very Low Fat Diet on Adipose Tissue and FFA Metabolism</td>
<td>Tracey L. McLaughlin, MD</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>The Prevention of T2 Diabetes</td>
<td>W. Timothy Garvey, MD</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>Aging Co-Morbidities - How We Can Stem Multiple Hallmarks of Aging to Treat Cardiometabolic Diseases: Dolphin Models</td>
<td>Stephanie Venn-Watson, DVM, MPH</td>
</tr>
<tr>
<td>4:40 pm</td>
<td>Obesity &amp; Diabetes Related Cancers: Similarities and Differences</td>
<td>Derek LeRoith, MD, PhD</td>
</tr>
<tr>
<td>5:00 pm — 5:15 pm</td>
<td>Q+A Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>5:15 pm — 5:45 pm</td>
<td>Refreshment Break</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #2  JOURNAL OF METABOLISM & WCIRDC: JOINT SESSION ON INSULIN RESISTANCE & METABOLISM
**Chair:** Christos S. Mantzoros, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:45 pm</td>
<td>EIC Intro, Journal Progress, Topics</td>
<td>Christos S. Mantzoros, MD, PhD</td>
</tr>
<tr>
<td>5:50 pm</td>
<td>Mediterranean Diet Impact on Diabetes and Cardiometabolic Conditions</td>
<td>George A. Bray, MD, Nikolaos Perakakis, MD, PhD</td>
</tr>
<tr>
<td>6:10 pm</td>
<td>Exercise, Insulin Resistance, Diabetes and CVD</td>
<td>Stella Daskalopoulou, MD, Adrian Vella, MD</td>
</tr>
<tr>
<td>6:30 pm</td>
<td>Hormonal Pathways and Molecular Mechanisms Underlying Cardiometabolic Disorders</td>
<td></td>
</tr>
<tr>
<td>6:50 pm</td>
<td>Novel Therapies for Metabolic Disorders</td>
<td></td>
</tr>
<tr>
<td>7:10 pm</td>
<td>Young Investigator Award, Brain and Metabolism: The Next Frontier</td>
<td></td>
</tr>
<tr>
<td>7:20 pm — 7:25 pm</td>
<td>Post-CME Questions</td>
<td></td>
</tr>
</tbody>
</table>

### 7:30 pm — 9:30 pm  CME DINNER SYMPOSIUM
**EPA— Icosapent Ethyl – Role in Clinical Practice**
**Chairs:** Michael Miller, MD  •  Yehuda Handelsman, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 pm</td>
<td>Introduction &amp; Pre-CME Questions</td>
<td></td>
</tr>
<tr>
<td>7:40 pm</td>
<td>EPA – Outcome REDUCE-IT – CV Related Pathophysiology and Clinical Implications Results, Pathophysiology of EPA – Clinical Implications</td>
<td>Michael Miller, MD, William S. Weintraub, MD</td>
</tr>
<tr>
<td>8:00 pm</td>
<td>Economic Impact of EPA – Icosapent Ethyl – on Practice</td>
<td>Yehuda Handelsman, MD</td>
</tr>
<tr>
<td>8:15 pm</td>
<td>Contemporary Management Guidelines for ASCVD Prevention</td>
<td></td>
</tr>
<tr>
<td>8:30 pm</td>
<td>Patient Cases</td>
<td>James A. Underberg, MD, Aruna Pradhan, MD</td>
</tr>
<tr>
<td></td>
<td>A. Diabetes Primary Prevention</td>
<td>Sergio Fazio, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>B. Established CVD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Diabetes Established CVD</td>
<td></td>
</tr>
<tr>
<td>9:15 pm</td>
<td>Q&amp;A Panel Discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recognizing Features to Identify the Appropriate Patient for EPA — Icosapent Ethyl</td>
<td>Michael Miller, MD, William S. Weintraub, MD, Yehuda Handelsman, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Panel:</strong> Sergio Fazio, MD, PhD  •  Aruna Pradhan, MD  •  James A. Underberg, MD  •  William S. Weintraub, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Michael Miller, MD  •  Yehuda Handelsman, MD</td>
<td></td>
</tr>
<tr>
<td>9:30 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
6:45 am – 7:45 am  Breakfast Session  Non-CME
Actionable Insights to Optimize Time in Range with the FreeStyle Libre 14 Day System
Supported by: Abbott

7:00 am – 8:00 am  Registration | Coffee at Exhibit Hall
8:00 am – 8:10 am  Welcome & Introduction
8:10 am – 8:20 am  Pre-CME Questions
Yehuda Handelsman, MD, Chair

SESSION #3  TYPE 2 DIABETES IN YOUTH - MEDICATIONS
Chairs: Alan R. Sinaiko, MD • Philip Levy, MD

8:20 am  Comparisons from the RISE Medication Study: Are Youths with Early Onset Diabetes Responding Differently to Metformin and Insulin Treatment than Adults
Steven E. Kahn, MB, ChB
8:40 am  The Challenge of Managing Youth-Onset T2DM with Currently Approved Medications: Time to Change Strategies
Sonia Caprio, MD
9:00 am–9:10 am  Q&A Panel Discussion

SESSION #4  EMERGING SCIENCE
Chairs: Derek LeRoith, MD, PhD • W. Timothy Garvey, MD

9:10 am  Clusterin Impairs Hepatic Insulin Sensitivity and Adipocyte Clusterin Associates with Cardiometabolic Risk
Willa Hsueh, MD
9:30 am  Role of Leptin in Starvation and Diabetic Ketoacidosis
Gerald I. Shulman, MD, PhD
9:50 am  Sarcopenia of Aging – The link with Insulin Resistance, Cardiometabolic Disease, Diabetes
Elena Volpi, MD, PhD
10:10 am – 10:25 am  Q&A Panel Discussion

SESSION #5  THE STATUS OF CHF
Chairs: Peter J. Grant, MD • Zachary T. Bloomgarden, MD

10:55 am  Heart Failure with Preserved Ejection Fraction in Diabetes: A Benign Marker of Accelerated Aging
Mark Kearney, MD
11:15 am  Beyond the Myocardium with Heart Failure
Robert J. Chilton, DO
11:35 am – 11:50 am  Q&A Panel Discussion

SESSION #6  INSULIN SECRETION & CLEARANCE
Chairs: Tracey L. McLaughlin, MD • Bart Staels, PhD

11:50 am  What's Clear About Clearance
Richard N. Bergman, PhD
12:10 pm  The Balances of Insulin Secretion and Glucose Disposal in the Fed and Fasting States
David A. D’Alessio, MD
12:30 pm – 12:40 pm  Q&A Panel Discussion

SESSION #7  THE TIMI GROUP @ WCIRDC
Chairs: Robert P. Giugliano, MD • Erin Bohula May, MD, DPhil

2:40 pm  ENGAGE AF-TIMI 48: Patients with DM, AF on Oral Anticoagulants
Anna Plitt, MD
3:00 pm  CAMELLIA-TIMI 61: Prevention of New Onset Diabetes & Other Risk Factor Modifications with Lorcanerin
Erin Bohula May, MD, DPhil
3:20 pm  2019 Updates Dapagliflozin from DECLARE-TIMI 58
Stephen D. Wiviott, MD
3:40 pm  FOURIER and VESALIUS-CV: From Secondary Prevention of CV Events with Evolocumab in Diabetics (FOURIER) on to Primary Prevention (VESALIUS-CV)
Robert P. Giugliano, MD
4:00 pm – 4:15 pm  Q&A Panel Discussion
4:15 pm – 4:45 pm  Refreshment Break at Exhibit Hall

Reviewing A1C and Cardiovascular Safety Data in T2D Therapies
Supported by: Novo Nordisk
Robert Chilton, DO  Melissa L. Magwire, RN, MSN, CDE
**SESSION #8**

**MEDICAL DIETS**

Chairs: Ronald M. Krauss, MD • Samuel Klein, MD

- **4:45 pm**  Ketogenic Diet for Diabetes
- **5:05 pm**  Overview of Intermittent Fasting
- **5:25 pm**  Ketones, Integrative Metabolism, and the Failing Heart
- **5:45 pm**  Circadian Rhythms, Time-Restricted Eating, and Cardiometabolic Health
- **6:05 pm – 6:30 pm** Q+A Panel Discussion & Post-CME Questions

---

**DIABETES AND THE CARDIORENAL SYNDROME**

Chair: Peter A. McCullough, MD

- **7:30 pm**  Introduction & Pre-CME Questions
- **7:40 pm**  The Cardiorenal Syndrome in Diabetes, Epidemiology and Economic Impact Janani Rangaswami, MD
- **8:00 pm**  Classification, Pathophysiology and Diagnosis of The Cardiorenal Syndrome Peter A. McCullough, MD
- **8:20 pm**  Contemporary Approach to Management and Prognosis of the Cardiorenal Syndrome in Diabetes Hector O. Ventura, MD
- **8:40 pm**  Emerging Therapies: The SGLT2 Inhibitors in People with T2D at Risk for Cardiorenal Syndrome Mark E. Molitch, MD
- **9:00 pm**  Q&A Panel Discussion: Practice Implication of CRS- Management and Prevention - Case based Norman E. Lepor, MD

Panel: Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD • Peter A. McCullough, MD • Janani Rangaswami, MD • Hector O. Ventura, MD • Matthew R. Weir, MD

Moderator: Norman E. Lepor, MD

Post-CME Questions

**9:30 pm** Adjourn - Dessert Reception To Follow

---

**SESSION #9**

**HAS OUR VIEW ABOUT THE ETIOLOGY OF DIABETIC NEPHROPATHY BECOME TOO MYOPIC?**

Chairs: Ralph A. DeFronzo, MD • Christian W. Mende, MD

- **8:15 am**  Diabetic Nephropathy: The Ominous Octet and More Ralph A. DeFronzo, MD
- **8:35 am**  Hypoxia: The Real Culprit Responsible for Diabetic Kidney Disease Per-Henrik Groop, MD
- **8:55 am**  The Tubular Hypothesis of Diabetic Nephropathy Volker Vallon, MD
- **9:35 am – 9:55 am** Q&A Panel Discussion

---

**SESSION #10**

**ASCVD IN DM: PATHOPHYSIOLOGY, PREVENTION & MANAGEMENT**

Chairs: Bart Staels, PhD • Nikolaus Marx, MD

- **9:55 am**  Atherosclerosis Burden in T1DM, T2DM and the General Population Matthew J. Budoff, MD
- **10:15 am**  ESC/EASD 2019 Guidelines: The Prevention and Management of Cardiovascular Disease in Diabetes Peter J. Grant, MD
- **10:35 am – 10:50 am** Q+A Panel Discussion
- **10:50 am – 11:20 am** Refreshment Break at Exhibit Hall

---

**SESSION #11**

**CONTEMPORARY APPROACH TO MANAGING DIABETES**

Chairs: Daniel Einhorn, MD • Vivian A. Fonseca, MD

- **11:20 am**  Non-Insulin Medications in the Treatment of T1D- Focus on SGLT1 & 2 Inhibitors Satish K. Garg, MD
- **11:40 am**  Do We Still Have to Inject to Manage Diabetes? George Grunberger, MD
SESSION #12  SALK INSTITUTE SYMPOSIUM- INSULIN RESISTANCE: ORIGIN AND TREATMENT
Chair: Ronald M. Evans, PhD

2:15 pm  FGF1: Control of Adipose Remodeling and Insulin Sensitivity  Ronald M. Evans, PhD
2:35 pm  Inflammatory Links Between Obesity and Insulin Resistance  Alan R. Saltiel, PhD
2:55 pm  Rethinking the Role of the Brain in Glucose Homeostasis and Diabetes Pathogenesis  Michael W. Schwartz, MD
3:15 pm – 3:30 pm  Q+A Panel Discussion

SESSION #13  A GLIMPSE TO THE FUTURE - WHAT’S IN THE PIPELINE?  Non-CME
Chairs: Ralph A. DeFronzo, MD • Christos S. Mantzoros, MD, PhD

3:30 pm  AstraZeneca
3:45 pm  Medtronic
4:00 pm  Poxel
4:15 pm – 4:45 pm  Refreshment Break at Exhibit Hall
4:45 pm  Janssen
5:00 pm  Sanofi
5:15 pm – 5:30 pm  Q+A Panel Discussion

SESSION #14  FATTY LIVER DISEASE & NASH
Chairs: Paul Zimmet, AO, MD, PhD • Sonia Caprio, MD

5:30 pm  NAFLD and Cardiometabolic Outcomes: Pathophysiology and Emerging Therapies  Christos S. Mantzoros, MD, PhD
5:50 pm  The Role of Immune-Inflammation in NASH  Bart Staels, PhD
6:10 pm  Therapeutic Advances for NASH  Arun J. Sanyal, MD
6:30 pm – 6:45 pm  Q+A Panel Discussion & Post-CME Questions

SESSION #15  CIRCADIAN VS METABOLIC SYNDROME
Chairs: Samuel Klein, MD • Kurt GMM Alberti, DPhil

POINT-COUNTER-POINT: SHOULD THE METABOLIC SYNDROME BE CHANGED TO CIRCADIAN SYNDROME?
8:00 am  Yes  Paul Zimmet AO, MD, PhD
8:20 am  No  Robert H. Eckel, MD
8:40 am – 8:55 am  Q+A Panel Discussion
AWARD PRESENTATION  Presented by: Daniel Einhorn, MD & Vivian A. Fonseca, MD

8:55 am DISTINGUISHED LEADER IN INSULIN RESISTANCE

SESSION #16 IMPACT OF CVOT IN 2019
Chairs: Robert J. Chilton, DO • Nikolaus Marx, MD

9:00 am Management of the High-Risk Older Patient Based on the Contemporary CVOT
Richard E. Pratley, MD

9:20 am CHF & CVOTs- DEFINE-HF, DAPA-HF and THEMIS
Mikhail N. Kosiborod, MD

9:40 am Critical Appraisal of 2019 CVOT
Sanjay Kaul, MD

10:00 am – 10:15 am Q+A Panel Discussion

10:15 am – 10:35 am Refreshment Break

AWARD PRESENTATION  Presented by: Daniel Einhorn, MD & Paul Zimmet, AO, MD, PhD

10:35 am GERALD REAVEN DISTINGUISHED LEADER IN INSULIN RESISTANCE
Key Note
Insulin Resistance, Type 2 Diabetes, Cardiovascular Disease: Looking Back, Looking Forward
Zachary T. Bloomgarden, MD

SESSION #17 LIPIDS – TODAY AND TOMORROW
Chairs: Paul S. Jellinger, MD • Mikhail N. Kosiborod, MD

11:05 am Contemporary & Future Management of LDL
Sergio Fazio, MD, PhD

11:25 am Dyslipidemia Management - Beyond LDL - in the Prevention of ASCVD
Christie M. Ballantyne, MD

11:45 am – 12:00 pm Q+A Panel Discussion

CONCURRENT SESSIONS

CLINICAL WORKSHOPS

Lunch will be provided

12:00 pm – 1:00 pm

- Vaccinations in Diabetes
  Hiro Room

- Lipids — Intensive Management
  Club Room

- How to Use CGM
  Mandarin AB

- Kidney Disease — 2019 Prevention & Management
  Salon 6AB

SESSION #18 CONTEMPORARY ROLE OF OLDER MEDS IN THE MANAGEMENT OF DIABETES
Chairs: George Grunberger, MD • Richard E. Pratley, MD

1:00 pm Cardiovascular Safety of Sulfonylureas – The Long Journey from UGDP to CAROLINA
Nikolaus Marx, MD

1:20 pm Incorporating Generic Oral Anti-Hyperglycemic Medications in Treatment of DM
Vivian A. Fonseca, MD

1:40 pm The Role of Insulin in the Management of T2D in the CVOT Era
Matthew C. Riddle, MD

2:00 pm Hypoglycemia Impact on the Brain
Stephanie Amiel, MD

2:20 pm – 2:40 pm Q+A Panel Discussion

2:40 pm - 3:00 pm Refreshment Break

SESSION #19 CO-MORBIDITIES OF CHILDHOOD DIABETES
Chairs: Sonia Caprio, MD • Tracey L. McLaughlin, MD

3:00 pm Youth with Type 2 Diabetes Develop Complications More Often Than Type 1 Peers
Dana Dabelea, MD, PhD

3:20 pm Relation of Childhood Cardiovascular Risk Factors to Adult Cardiovascular Disease
Alan R. Sinaiko, MD

3:40 pm – 3:50 pm Q+A Panel Discussion

SESSION #20 INTERPRETING CVOT – IMPLICATIONS FOR PRACTICE
Chairs: Vivian A. Fonseca, MD • Peter J. Grant, MD

DEBATE: THE APPROPRIATE MEDICATION PREVENTING THE NEXT EVENT IN A PATIENT WITH DM & ESTABLISHED CVD?

3:50 pm Case Presentation
Yehuda Handelsman, MD

3:55 pm SGLT2i
Sunder Mudaliar, MD

4:05 pm PCSK9i
Sergio Fazio, MD, PhD

4:15 pm GLP-1-ra
Richard E. Pratley, MD

4:25 pm EPA
Christie M. Ballantyne, MD

4:35 pm - 5:00 pm Q+A Panel Discussion & Post-CME Questions

5:00 pm Adjourn